The human growth hormone market registered a market size of USD 4,142.83 million in 2020, and it is expected to reach USD 8,147.41 million by 2028, registering a CAGR of 9.32% during the forecast period, 2021-2028.
The human growth hormone (HGH) is produced in the pituitary gland and is the master hormonal gland secretory organ responsible for the human body’s proper development and growth. When HGH is a deficiency in adults, the results are stunted growth and stunted life span as well. There are three major forms of HGH deficiency namely serum hypogonadism, hypophysectomy, and pituitary glandectomies. Hypogonadism refers to the absence of the human growth hormone in the pituitary gland; whereas hypophysectomy is the surgical removal of the pituitary gland. In this case, the normal gland is removed along with the extra glandular tissue. Another form of this deficiency is polycystic hormone deficiency or PTH deficiency, where an excessive amount of hormone is produced by the pituitary gland, stimulating the production of the additional hormone.
Request for Sample Copy of Report with Analysis of COVID-19 Impact on Human Growth Hormone Market – https://www.stratagemmarketinsights.com/sample/14223
The global human growth hormone market is expected to grow on the account of the presence of a strong pipeline and increasing R&D activities. The growing prevalence of human growth hormone deficiency is again fostering the growth of the market. According to data published by the American Academy of Pediatrics, growth hormone deficiency among humans is a rare condition and affects less than one in 3,000 to one in 10,000 children in U.S. Currently, HGH is widely abused as an anti-aging treatment in older adults and as a performance-enhancing anabolic drug by bodybuilders and athletes.
Human Growth Hormone Market – Competitor Analysis
Novo Nordisk, Pfizer, Eli Lilly, Merck Serono, F. Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen, LG Life Sciences, Sandoz International, Anhui Anke Biotechnology
Human Growth Hormone Market – Regional Analysis
North America is expected to gain significant growth over the forecast period and this is attributed to the rising drug approval for the treatment of human growth hormone deficiency. For instance, in January 2018, Ferring Pharmaceuticals Inc. received USFDA approval for its new recombinant HGH, Zomacton (somatropin), indicated for the treatment of adults with GH deficiency.
Human Growth Hormone Market – Key Developments
- In October 2019, Pfizer Inc. and its partner OPKO Health Inc. announced that its Phase III study investigating Somatrogon in pre-pubertal children with hGH met its primary endpoint of non-inferiority to daily somatropin
- In March 2017, Novo Nordisk A/S, a Denmark-based pharmaceutical company, initiated the phase III clinical trial of its HGH somapacitan, indicated for the treatment of adult growth hormone deficiency, in Japan
- In October 2020, Pfizer Inc. and OPKO Health Inc. announced that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in children 3 to <18 years of age with growth hormone deficiency (GHD), met its primary endpoint of improved treatment burden compared to GENOTROPIN® (somatropin) for injection administered once-daily.
Buy now this Premium Report to grow your Business: https://www.stratagemmarketinsights.com/cart/14223
Reasons to Purchase this Report:
- The trendy developments, market shares, and strategies that are employed by means of the essential market players
- The segment that is anticipated to dominate the market as properly as the segment which holds the highest CAGR in the forecast period
- Current and future of global Cough Syrup market outlook in the developed and rising markets
- Regions/countries that are anticipated to witness the quickest growth rates at some stage in the forecast period
Human Growth Hormone Market – Segmentation
By Type:
- Powder
- Solvent
By Application:
- Growth Hormone Deficiency (GHD)
- Turner Syndrome
- Chronic Renal Insufficiency
- Prader Willi Syndrome
- Small for Gestational Age
Frequently Asked Questions:
- What is the scope of the report?
- Does this report estimates the current market size?
- Does the report provides Market Size in terms of – Value (US$ MN) and Volume (Thousands of Units) – of the market?
- Which segments are covered in this report?
- What are the key factors covered in this report?
- Does this report offer customization?
Inquire to Know More About This Report @ https://www.stratagemmarketinsights.com/quiry/14223
About Us:
Stratagem Market Insights is a management consulting organization providing market intelligence and consulting services worldwide. We bring the expertise of consultants with a cumulative industry experience of more than 70 years. The firm has been providing quantified B2B research and currently offers services to over 350+ customers worldwide.
We strive to offer a sapient solution, expert consultations, and tailored/customized solutions. Our team includes analysts that leverage their years of experience and expertise to create accurate and error-free reports. The domain-specific teams are constantly focused on tracking markets, aiding our clients to gain a competitive edge through high-quality market intelligence. We offer an array of services including, syndicated research, advisory and consulting research process outsourcing, and content management.
Contact Us:
Mr. Shah
Stratagem Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027 / JAPAN +815055391737
Email: sales@stratagemmarketinsights.com